Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Young Kwon sold 531 shares of the stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $25.70, for a total transaction of $13,646.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Young Kwon also recently made the following trade(s):

  • On Wednesday, August 8th, Young Kwon sold 632 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $29.00, for a total transaction of $18,328.00.
  • On Wednesday, July 18th, Young Kwon sold 35,164 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $29.33, for a total transaction of $1,031,360.12.
  • On Thursday, July 12th, Young Kwon sold 46,499 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $25.44, for a total transaction of $1,182,934.56.
  • On Tuesday, June 5th, Young Kwon sold 1 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $24.90, for a total transaction of $24.90.
  • On Wednesday, May 23rd, Young Kwon sold 17,500 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $23.90, for a total transaction of $418,250.00.
  • On Monday, May 21st, Young Kwon sold 15,351 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $22.91, for a total transaction of $351,691.41.

Shares of MNTA opened at $25.60 on Tuesday. Momenta Pharmaceuticals, Inc. has a fifty-two week low of $11.85 and a fifty-two week high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.50). The business had revenue of $13.00 million during the quarter, compared to analysts’ expectations of $15.83 million. Momenta Pharmaceuticals had a negative return on equity of 40.55% and a negative net margin of 128.49%. Momenta Pharmaceuticals’s revenue for the quarter was down 44.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.50) EPS. analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.89 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in shares of Momenta Pharmaceuticals during the second quarter valued at approximately $108,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Momenta Pharmaceuticals during the fourth quarter valued at approximately $163,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Momenta Pharmaceuticals during the first quarter valued at approximately $254,000. Amalgamated Bank grew its holdings in shares of Momenta Pharmaceuticals by 16.1% during the second quarter. Amalgamated Bank now owns 12,544 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 1,739 shares during the last quarter. Finally, Profund Advisors LLC grew its holdings in shares of Momenta Pharmaceuticals by 33.1% during the first quarter. Profund Advisors LLC now owns 15,483 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 3,853 shares during the last quarter. Institutional investors and hedge funds own 94.65% of the company’s stock.

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of Momenta Pharmaceuticals in a research note on Thursday, June 14th. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st. BidaskClub cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, June 23rd. ValuEngine cut shares of Momenta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 21st. Finally, TheStreet cut shares of Momenta Pharmaceuticals from a “c-” rating to a “d” rating in a report on Tuesday, May 8th. Seven analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $17.38.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Featured Article: Short Selling

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.